CBD Life Sciences Inc. (CBDL) Announces New Delta-8 100MG Gummies Designed to Support Individuals Living With Alzheimer’s
CBD Life Sciences Inc. (CBDL) has launched Delta-8 100mg Gummies specifically designed for Alzheimer's patients, targeting the $6 billion U.S. edibles market. The product aims to address symptoms like anxiety, restlessness, and agitation in Alzheimer's patients, with projected first-year revenue of $3 million. The gummies feature natural ingredients, precise dosing, and third-party testing for safety and efficacy.
The company reports a 1405.46% revenue increase since February 2024, positioning itself in a market segment where cannabinoid use among seniors has grown 300% over the past decade. With the U.S. Alzheimer's population expected to reach 12.7 million by 2050, CBDL aims to meet growing demand for natural alternatives in elderly care.
CBD Life Sciences Inc. (CBDL) ha lanciato Delta-8 100mg Gummies specificamente progettate per pazienti affetti da Alzheimer, mirando al mercato degli edibili negli Stati Uniti da 6 miliardi di dollari. Il prodotto si propone di affrontare sintomi come ansia, irrequietezza e agitazione nei pazienti affetti da Alzheimer, con un fatturato previsto per il primo anno di 3 milioni di dollari. Le caramelle gommose hanno ingredienti naturali, dosaggi precisi e test di terze parti per sicurezza ed efficacia.
L'azienda riporta un aumento del fatturato del 1405,46% da febbraio 2024, posizionandosi in un segmento di mercato dove l'uso di cannabinoidi tra gli anziani è cresciuto del 300% nell'ultimo decennio. Con la popolazione degli alzheimer negli Stati Uniti che dovrebbe raggiungere 12,7 milioni entro il 2050, CBDL mira a soddisfare la crescente domanda di alternative naturali nella cura degli anziani.
CBD Life Sciences Inc. (CBDL) ha lanzado Gomitas de Delta-8 100mg diseñadas específicamente para pacientes con Alzheimer, apuntando al mercado de comestibles en EE.UU. de 6 mil millones de dólares. El producto tiene como objetivo abordar síntomas como la ansiedad, la inquietud y la agitación en pacientes con Alzheimer, con un ingreso proyectado para el primer año de 3 millones de dólares. Las gomitas cuentan con ingredientes naturales, dosificación precisa y pruebas de terceros para garantizar seguridad y eficacia.
La empresa informa un aumento del 1405,46% en los ingresos desde febrero de 2024, posicionándose en un segmento de mercado donde el uso de cannabinoides entre los ancianos ha crecido un 300% en la última década. Con la población de Alzheimer en EE.UU. proyectada para alcanzar 12,7 millones para 2050, CBDL busca satisfacer la creciente demanda de alternativas naturales en el cuidado de los ancianos.
CBD Life Sciences Inc. (CBDL)는 알츠하이머 환자를 위해 특별히 설계된 Delta-8 100mg 젤리를 출시하여 60억 달러 규모의 미국 간식 시장을 겨냥하고 있습니다. 이 제품은 알츠하이머 환자에게 나타나는 불안, 안절부절함, 초조함 등의 증상을 완화하는 것을 목표로 하며, 첫 해 매출 목표는 300만 달러입니다. 젤리는 천연 성분, 정확한 용량, 그리고 안전성과 효능을 위한 제3자 테스트를 특징으로 합니다.
회사는 2024년 2월 이후 매출이 1405.46% 증가했다고 보고하며, 지난 10년 동안 노인들 사이에서 칸나비노이드 사용이 300% 증가한 시장 세그먼트에 자리를 잡고 있습니다. 2050년까지 미국의 알츠하이머 환자 수가 1270만 명에 이를 것으로 예상됨에 따라, CBDL은 노인 돌봄에 있어 자연 대체품에 대한 증가하는 수요를 충족할 계획입니다.
CBD Life Sciences Inc. (CBDL) a lancé Delta-8 100mg Gummies spécialement conçues pour les patients atteints d’Alzheimer, visant le marché des produits comestibles aux États-Unis de 6 milliards de dollars. Le produit vise à atténuer des symptômes tels que l'anxiété, l'agitation et l'irritabilité chez les patients atteints d'Alzheimer, avec un chiffre d'affaires prévisionnel de 3 millions de dollars pour la première année. Les gommes contiennent des ingrédients naturels, un dosage précis et des tests de tiers pour la sécurité et l'efficacité.
La société signale une augmentation de 1405,46 % de son chiffre d'affaires depuis février 2024, se positionnant dans un segment de marché où l'utilisation des cannabinoïdes chez les personnes âgées a augmenté de 300 % au cours de la dernière décennie. Avec une population d'Alzheimer aux États-Unis qui devrait atteindre 12,7 millions d'ici 2050, CBDL vise à répondre à la demande croissante d'alternatives naturelles dans les soins aux personnes âgées.
CBD Life Sciences Inc. (CBDL) hat Delta-8 100mg Gummies speziell für Alzheimer-Patienten auf den Markt gebracht und zielt auf den 6-Milliarden-Dollar-Markt für essbare Produkte in den USA ab. Das Produkt soll Symptome wie Angst, Unruhe und Agitation bei Alzheimer-Patienten ansprechen, mit einem prognostizierten Jahresumsatz von 3 Millionen Dollar. Die Gummibärchen enthalten natürliche Zutaten, präzise Dosierung und Tests durch Dritte zur Sicherheit und Wirksamkeit.
Das Unternehmen berichtet von einem Umsatzanstieg von 1405,46% seit Februar 2024 und positioniert sich in einem Marktsegment, in dem die Verwendung von Cannabinoiden bei Senioren in den letzten zehn Jahren um 300% gestiegen ist. Da die Zahl der Alzheimer-Patienten in den USA bis 2050 voraussichtlich 12,7 Millionen erreichen wird, strebt CBDL an, die wachsende Nachfrage nach natürlichen Alternativen in der Altenpflege zu bedienen.
- Projected $3 million revenue in first year from new product line
- 1405.46% revenue increase since February 2024
- Entry into $6 billion U.S. edibles market
- Product targets growing demographic with Alzheimer's population expected to reach 12.7 million by 2050
- None.
Targeting a booming
SCOTTSDALE, ARIZONA / ACCESSWIRE / December 3, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in cannabinoid innovation, proudly announces the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions.
CBD Life Sciences' entry into this specialized segment of the
A Product Born from Real Needs and Scientific Innovation
The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.
Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief.
Lisa Nelson, President and CEO of CBD Life Sciences Inc., shared:
"Our mission has always been to create products that genuinely improve lives. With our Delta-8 Gummies, we're addressing a critical gap in Alzheimer's care by offering a natural, effective alternative that families and caregivers can trust. This launch also marks an exciting growth opportunity for our company as we expand into a high-demand market segment."
Revenue and Growth Potential
The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional
The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a
Meeting the Needs of an Underserved Market
CBD Life Sciences' Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy.
The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care.
CBD Life Sciences: Setting the Standard in Innovation
The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a
This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a forward-thinking company dedicated to developing and commercializing cannabinoid-based health and wellness solutions. With a diverse product portfolio that includes pain relief creams, nano CBD beverages, and Delta-8 edibles, CBD Life Sciences aims to improve lives while delivering exceptional value to its shareholders.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
|
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is the projected first-year revenue for CBDL's new Delta-8 gummies?
What is CBDL's revenue growth since February 2024?
What market size is CBDL targeting with their new Delta-8 gummies?
What symptoms do CBDL's Delta-8 gummies address in Alzheimer's patients?
